These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19593615)

  • 1. Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC).
    Abdelwahab S; Abdulla H; Azmy A; Abdelfatah A; Abdel-Aziz H; Margerges M; Riad A; Sharma V; Dwedar I
    Int J Clin Oncol; 2009 Jun; 14(3):230-6. PubMed ID: 19593615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
    Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
    Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer.
    Sohn JH; Moon YW; Lee CG; Kim GE; Chung KY; Chang J; Kim SK; Kim YS; Choi BW; Choi HJ; Kim JH
    Cancer; 2007 May; 109(9):1845-950. PubMed ID: 17366589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer.
    Jeong HC; Lee SY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
    Lung Cancer; 2006 Sep; 53(3):361-6. PubMed ID: 16846662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer.
    Wahba HA; Halim AA; El-Hadaad HA
    Med Oncol; 2012 Mar; 29(1):199-204. PubMed ID: 21140241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.
    Fukuda M; Nakamura Y; Kinoshita A; Soejima Y; Yamaguchi H; Ikeda T; Izumikawa K; Takatani H; Fukuda M; Soda H; Hayashi N; Tsukamoto K; Oka M; Kohno S
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):645-51. PubMed ID: 23010852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
    Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
    J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
    Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
    Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
    Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
    Kudoh S; Fujiwara Y; Takada Y; Yamamoto H; Kinoshita A; Ariyoshi Y; Furuse K; Fukuoka M
    J Clin Oncol; 1998 Mar; 16(3):1068-74. PubMed ID: 9508192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
    Sorensen M; Lassen U; Palshof T; Jensen BB; Johansen J; Jensen PB; Langer SW
    Lung Cancer; 2008 May; 60(2):252-8. PubMed ID: 18036701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
    Lee JE; Park HS; Jung SS; Kim JO; Kim SY
    Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I study.
    de Jong WK; de Jonge MJ; van der Leest AH; van Meerbeeck JP; Groen HJ
    Lung Cancer; 2008 Jul; 61(1):123-8. PubMed ID: 18179842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
    Misumi Y; Okamoto H; Sasaki J; Masuda N; Ishii M; Shimokawa T; Hosomi Y; Okuma Y; Nagamata M; Ogura T; Kato T; Sata M; Otani S; Takakura A; Minato K; Miura Y; Yokoyama T; Takata S; Naoki K; Watanabe K
    BMC Cancer; 2017 May; 17(1):377. PubMed ID: 28549414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
    Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
    J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.
    Han JY; Lee DH; Lee SY; Park CG; Kim HY; Kim EA; Yoon SM; Lee HG; Lee JS
    Med Oncol; 2005; 22(3):281-90. PubMed ID: 16110139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.
    Bae SH; Ryoo HM; Do YR; Song HS; Kwon KY; Kim MK; Lee KH; Hyun MS; Lee WS; Hur IK; Baek JH; Park KU
    Lung Cancer; 2008 Jan; 59(1):76-80. PubMed ID: 17767977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.